At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
Andrew W. Hahn, MD
Advertisement
Articles by Andrew W. Hahn, MD
Andrew W. Hahn, MD, discusses the investigation of lenvatinib plus everolimus vs cabozantinib in metastatic renal cell carcinoma following progression on an immune checkpoint inhibitor.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5